

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of December 2023

	31.12.2023	31.12.2022
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	33 678	35 319
Intangible assets	3 560	3 761
Investments in subsidiaries	19	19
Trade receivables	4 978	5 076
Total non-current assets	42 235	44 175
Current assets		
Inventories	14 303	13 480
Trade and other receivables	65 895	62 056
Current corporate income tax	-	27
Cash and cash equivalents	60	126
Total current assets	80 258	75 689
Total assets	122 493	119 864
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 782	12 498
Retained earnings	8 158	4 591
Total	105 440	101 589
Non-current liabilities		
Long-term loans	835	1 399
Deferred tax liabilities	1 042	1 042
Retirement benefit obligations	191	191
Total non-current liabilities	2 068	2 632
Current liabilities		
Trade and other liabilities	4 470	5 079
Short-term loans	9 791	9 785
Current portion of long-term loans	481	620
Other tax liabilities	243	159
Total current liabilities	14 985	15 643
Total liabilities	17 053	18 275
Total equity and liabilities	122 493	119 864

Date of preparation: 25.01.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of December 2023

	31.12.2023	31.12.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	48 512	43 146
Other income	67	721
Total income	48 579	43 867
Carrying amount of goods sold	(862)	(752)
Changes in inventories of finished products and work in progress	(231)	1 896
Materials and services	(32 399)	(31 918)
Personnel expenses	(6 976)	(6 023)
Depreciation / amortisation expenses	(2 809)	(3 568)
Other expenses	(899)	(456)
Finance income	536	574
Finance costs	(668)	(487)
Total expenses	(44 308)	(40 734)
Profit before taxation	4 271	3 133
Corporate income tax expense	(420)	(342)
Profit/Loss for the period	3 851	2 791
		(24)
Total comprehensive income for the period	3 851	2 767
Earnings per share / in BGN per 1 share /	0.05	0.03

Date of preparation: 25.01.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....


/B. Georgiev/


Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of December 2023

	31.12.2023	31.12.2022
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	33 521	33 019
Payments to suppliers of materials, goods and services	(18 136)	(19 600)
Payments to personnel	(6 580)	(5 433)
Foreign currency exchange gains/losses	(23)	(44)
Payments of interest and dividends	(393)	(445)
Other proceeds / payments	(5 522)	(5 035)
<i>Net cash flows</i>	2 867	2 462
Cash flows from investing activities		
Payments on non-current assets acquired	(1 912)	(1 580)
<i>Net cash flows</i>	(1 912)	(1 580)
Cash flows from financial activities		
Proceeds from loans	527	247
Payments on loans	(527)	(248)
Payment of interest, dividends	(499)	(273)
Payments on finance lease	(522)	(522)
<i>Net cash flows</i>	(1 021)	(796)
Change in cash and cash equivalents	(66)	86
Cash and cash equivalents at the beginning of the period	126	40
Cash and cash equivalents at the end of the period	60	126

Date of preparation: 25.01.2024

Sofia

Prepared by:.....

 / P. Moneva /

Executive
 Director:.....

 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of December 2023

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2022	84 500	4 375	8 007	1 940	98 822
Profit/loss for the period				2 791	2 791
Other comprehensive income		(24)			(24)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(24)		2 791	2 767
Issue of shares by the owners			140	(140)	
Dividends accrued			140	(140)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2022	84 500	4 351	8 147	4 591	101 589
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				3 851	3 851
Other comprehensive income					
Total comprehensive income				3 851	3 851
Issue of shares by the owners			284	(284)	
Total amount of income and expenses recognised during the period			284	(284)	
Balance as of 31.12.2023	84 500	4 351	8 431	8 158	105 440

Date of preparation: 25.01.2024
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/